BioLife Solutions, Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $25.4 million, a 29% increase from $19.7 million in the same period last year. The growth was primarily driven by a significant rise in product revenue, which reached $23.7 million, up from $18.1 million in the prior year, reflecting a 31% increase. For the first half of 2025, total revenue was $49.4 million, compared to $38.1 million in the first half of 2024, marking a similar 29% growth. Despite the revenue increase, the company reported a net loss of $15.8 million for the quarter, compared to a loss of $20.7 million in the same quarter of 2024.
The financial performance was impacted by a substantial rise in operating expenses, which totaled $42.1 million for the quarter, a 100% increase from $21.0 million in the previous year. This increase was largely attributed to a one-time in-process research and development (IPR&D) expense of $15.5 million related to the acquisition of PanTHERA, as well as higher general and administrative costs driven by increased personnel and stock-based compensation expenses. The company’s total operating loss for the first half of 2025 was $17.9 million, compared to a loss of $4.6 million in the same period last year.
In terms of strategic developments, BioLife Solutions completed the acquisition of PanTHERA on April 4, 2025, which is expected to enhance its capabilities in biopreservation technology. The company also divested several subsidiaries, including Global Cooling, SciSafe, and Custom Biogenic Systems, in 2024 to streamline its operations and focus on higher-margin products. These divestitures have been classified as discontinued operations in the financial statements, allowing the company to concentrate on its core bioproduction products and services.
Operationally, BioLife Solutions has seen an increase in customer demand, particularly for its cell processing products, which contributed significantly to the revenue growth. The company reported a 28% increase in revenue from cell processing products for the second quarter, driven by a recovery in customer purchasing patterns. The company’s cash and cash equivalents stood at $31.9 million as of June 30, 2025, down from $95.4 million at the end of 2024, primarily due to cash outflows related to acquisitions and divestitures.
Looking ahead, BioLife Solutions anticipates that its current cash reserves will be sufficient to meet liquidity needs for at least the next twelve months. The company is focused on leveraging its recent acquisitions and divestitures to enhance its market position in the cell and gene therapy industry. However, it acknowledges potential risks related to market conditions and operational execution as it continues to navigate the evolving landscape of bioproduction and biopreservation technologies.
About BIOLIFE SOLUTIONS INC
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.